IQ-AI Limited Placing (4081D)
June 26 2019 - 1:00AM
UK Regulatory
TIDMIQAI
RNS Number : 4081D
IQ-AI Limited
26 June 2019
IQ-AI Ltd
("IQ-AI" or the "Company")
Placing
Following strong demand from existing and new shareholders,
IQ-AI is pleased to announce that it has raised GBP250,000 through
the placing of 7,142,857 new ordinary shares (the "Placing Shares")
at a price of 3.5 pence per Placing Share (the "Placing Price")
(the "Placing") through Peterhouse Capital Limited, the Company's
Financial Adviser and Broker.
The funds will be used to accelerate the development of our
current Imaging Biometrics Artificial Intelligence ("AI") projects,
including Stone Checker, in response to rapidly growing interest in
these technologies by medical practitioners.
It is expected that the Placing shares will commence trading at
8.00am on 1 July 2019.
Following completion of the Placing, the Company's issued share
capital will consist of 127,489,352 ordinary shares of 1 penny
each. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Fungai Ndoro
Tel: 020 7220 9797
----------------------------------------------------------
About IQ-AI Ltd
IQ-AI, Ltd, the parent company of StoneChecker(R) and Imaging
Biometrics(R), is focused on advanced and state of the art medical
software and services. (IQ-AI.ltd). Imaging Biometrics develops and
provides visualization and analytical solutions that enable
clinicians to better diagnose and treat diseases with greater
confidence. Through close collaboration with top researchers and
clinicians, sophisticated advancements are translated into
platform-independent software plug-ins which can extend the base
functionality of workstations, imaging systems, PACS, or medical
viewers. By design, IB's advanced visualization software seamlessly
integrates into routine workflows. Please visit
www.imagingbiometrics.com for further information.
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEUVRBRKUANUAR
(END) Dow Jones Newswires
June 26, 2019 02:00 ET (06:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024